WO1991000727A1 - Substituted 2-aminotetralins - Google Patents

Substituted 2-aminotetralins Download PDF

Info

Publication number
WO1991000727A1
WO1991000727A1 PCT/US1990/003761 US9003761W WO9100727A1 WO 1991000727 A1 WO1991000727 A1 WO 1991000727A1 US 9003761 W US9003761 W US 9003761W WO 9100727 A1 WO9100727 A1 WO 9100727A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
oxygen
compound
propyl
carbon atoms
Prior art date
Application number
PCT/US1990/003761
Other languages
French (fr)
Inventor
James V. Peck
Gevork Minaskanian
Original Assignee
Whitby Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitby Research, Inc. filed Critical Whitby Research, Inc.
Publication of WO1991000727A1 publication Critical patent/WO1991000727A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/16—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the invention relates generally to substituted 2-aminotetralins and to processes for preparing such compounds. More particularly, the invention relates to compounds for therapeutic use, in particular in treating disorders of the central nervous, cardiovascular and endocrine systems. The compounds of this invention are also useful for alleviating glaucoma, parkinsonism, and schizophrenia, and for inducing anorexia and weight loss in mammals.
  • R 1 and R 2 are saturated alkyl groups and n is 1 or 2 , are dopamine receptor agonists (McDermed et al., J. Med. Chem. 18 , 362 (1975); Feenstra et al., Arch. Pharmacol. 313, 213 (1980). Many structure-activity relationship studies have been conducted to find compounds with high dopamine-receptor stimulating activity. A survey is contained in Katerinopoulos, H. E., et al., "Structure-Activity Relationships for Dopamine Analogues," Drugs of the Future. Vol. 12, No. 3, 1987, 223-253.
  • D 2 receptor potency of dopamine agonists is at a maximum when one of the two N-substituents fits into a receptor niche which, because of size constraints maximally accommodates an n-propyl group Conversely, activity drops off when the propyl group is replaced by the smaller groups ethyl or methyl. When the compound contains no N-substituent at least as small as n-propyl, activity is small or non-existent.
  • R 2 , R 3 and R 4 are each selected from the group consisting of H and OA with the provision that at least one of R 2 , R 3 and R 4 is H, that R 2 and R 4 are not both OA;
  • A is H or is selected from the group consisting of hydrocarbyl radicals, for example lower alkyl radicals optionally substituted with aromatic residues (i.e. methyl, ethyl, propyl, benzyl, etc.), as well as and
  • R 5 is selected from the group consisting of alkyl and aromatic residues having between 1 and 12, preferably between 1 and 6, carbon atoms, for example alkyl, optionally sub ⁇ titued with aromatic residues, and aromatic residues optionally substituted with alkyl radicals; n is an integer between 1 and 4; R 6 is an alkyl chain comprising between 1 and 4 carbon atoms, X is selected from the group consisting of -CH 2 -, oxygen, sulfur, and nitrogen, with the provision that when X is not -CH 2 -, R 1 is selected from the group consisting of
  • Z is oxygen, nitrogen or sulfur
  • Y is selected from the group consisting of hydroxy, nitro, cyano, azido, amino, acylamino, carbpxyamido, trifluoromethyl, sulfate, sulfonamido, halogen, hydrocarbyl, and hetero atom-substituted hydrocarbyl radicals, wherein said heteroatoms are selected from the group consisting of halogen, nitrogen, oxygen, sulfur and phosphorus and said hydrocarbyl radicals comprise from 1 to 12 carbon atoms, and a is an integer of from zero to 3; and with the further provision that when X is -CH 2 -, R 1 is either or
  • R 8 is hydrogen, aryl, or R 6 ; and further wherein R 9 is aryl, R 6' -OH, -NH 2 , -OR 6 , or -N(R 6 ) 2 ; or R 1 is
  • B is oxygen, sulfur or two hydrogen atoms, and pharmaceutically acceptable salts thereof.
  • R 2 is OA and A is H.
  • the compounds in the present invention be an optically active compound or racemic mixture thereof having substantial affinity and selectivity for binding to dopamine D 2 receptors, e.g., in a human.
  • 2-(N-n-propyl,N-2-[phenyloxy]ethylamino)-5-hydroxytetralin is especially preferred for its high affinity and selectivity for binding to dopamine D 2 receptors.
  • R 2 , R 3 and R 4 are each selected from the group consisting of H and OA with the provision that at least one of R 2 R 3 and R 4 is H, that R 2 and R 4 are not both OA;
  • A is H or is selected from the group consisting of hydrocarbyl radicals, for example lower alkyl radicals, optionally substituted with aromatic residues (i.e. methyl, ethyl, propyl, benzyl, etc.),
  • R 5 is selected from the group consisting of alkyl and a tic residues having between 1 and 12, preferably between 1 and 6, carbon atoms, for example alkyl residues optionally substituted with aromatic residues and aromatic residues optionally substituted with alkyl radicals; n is an integer between 1 or 4; R 6 is an alkyl chain comprising between 1 and 4 carbon atoms; X is selected from the group consisting of -CH 2 -, oxygen, sulfur, and nitrogen, with the provision that when X is not -CH 2 -, R is selected from the group consisting of
  • Z is oxygen, nitrogen or sulfur
  • Y is selected from the group consisting of hydroxy, nitro, cyano, azido, amino, acylamino, carboxyamido, trifluoromethyl, sulfate, sulfonamido, halogen, hydrocarbyl and hetero atom-substituted hydrocarbyl radicals, wherein said heteroatoms are selected from the group consisting of halogen, nitrogen, oxygen, sulfur and phosphorus and said hydrocarbyl radicals comprise from 1 to 12, preferably 1 to 6, carbon atoms, and a is an integer of from zero to 3, for instance zero to 2; and with the further provision that when X is -CH 2 -, R 1 is either
  • R 8 is hydrogen, aryl, or R 6 ; and further wherein R 9 is aryl, R 6 , -OH, -NH 2, -OR 6 , or -N(R 6 ) 2 ;
  • B is oxygen, sulfur or two hydrogen atoms, and pharmaceutically acceptable salts thereof.
  • R 2 is OA and A is H.
  • A is preferably H or is selected from the group consisting of phenyl and alkyl radicals having from 1 to 12 carbon atoms, and more preferably R 5 is an alkyl or aryl radical that would serve to extend the activity of the compound in the body, for example phenyl, methyl, t-butyl, o-methylphenyl, o-, m- or p-methoxyphenyl, p-isopropylphenyl or nonyl.
  • R The more preferred groups represented by R are thienyl, phenyl, hydroxyphenyl, furanyl and naphthalenyl, e.g., 2-thienyl, 3-thienyl, 3 -hydroxyphenyl, 4-hydroxyphenyl, etc.
  • n 2
  • X oxygen or -CH 2 - and R 2 is OA; and most preferably A is H and R 6 is propyl.
  • the compounds herein be an optically active or racemic mixtures capable of binding selectively to one or more dopamine D 2 receptors, e.g., in a human.
  • 2-(N-n-propyl,N-2-[phenyloxy] ethylamino)-5-hydroxytetralin is an especially preferred compound because of its high affinity and selectivity for binding to D 2 dopamine receptors.
  • the compounds herein will be useful in the treatment of disorders of the central nervous, cardiovascular, and endocrine systems. In particular it is believed that the compounds herein are useful in the treatment of such conditions in humans as elevated intraocular pressure, schizophrenia and parkinsonism, and for inducing anorexia and weight loss in humans and other mammals.
  • Y comprises no more than 5 carbon atoms and a is an integer from 0 to 2.
  • Specific preferred compounds of this group include:
  • R 1 is phenyl and/or substituted phenyl and is selected from the group of radicals represented by the formula:
  • Example 2 The product of Example 2 was also obtained by dissolving the product of Example 1 in dry dichloromethane and adding a solution of boron tribromide in dichloromethane dropwise at room temperture under nitrogen. After completion, the reaction was poured into a beaker containing NH 4 OH and ice and stirred for 0.5 h. The organic layer was separated, and the product was purified as in Example 2.
  • Example 1 phenoxyacetic acid can be replaced by 3-phenoxy-propionic acid.
  • Example 1 phenoxyacetic acid was replaced by (1-naphthoxy)-acetic acid.
  • the resulting oil was sujbected to flash chromatography (silica; pet ether) and the product was isolated; characteristic peak of NMR (300 MHz, CDCl 3 ); ⁇ 8.3-6.7 (m,10H), 4.2(m, 2H), 3.85(s, 3H), 1.0(t, 3H).
  • Example 6 The product of Example 6 was used as the starting material in Example 2. The resulting oil was subjected to flash chromatography and the isolated product showed characteristic peaks at : NMR (CDCl 3 ) ⁇ 8.3-6.6 (m, 10H), 4.2(m, 2H), 0.9(t,3H).
  • Example 1 phenoxyacetic acid was replaced by phthalide-3-acetic acid. The resulting oil was subjected to flash chromatography and the isolated product showed distinct peaks at: NMR (CDCl 3 ) ⁇ 8.0-6.7(m, 7H) , 5.7(m, 1H), 3.8(s, 3H), 0.9 (t, 3H).
  • NMR CDCl 3
  • Example 8 The product of Example 8 was used as the starting material for Example 3.
  • the resulting oil after purification showed distinct peaks at: NMR(CDC1 3 ) ⁇ 7.9-6.6(m, 7H), 5.7(m, 1H), 0.95(t, 3H).
  • Example 1 phenoxyacetic acid was replaced by diphenylactic acid.
  • the purified product showed characteristic peaks at: NMR(CDCl 3 ) ⁇ 7.8-6.65(m, 13H), 4.1(t, 1H), 3.8(s, 3H), 3.2(d, 2H), 0.7(t, 3H).
  • Example 1 phenoxyacetic acid was replaced by 3,3-diphenylpropionic acid.
  • the purified product showed distinct peaks at: NMR(CDCl 3 ) ⁇ 7.4-7.2 (m, 11H), 6.65(m, 2H), 4.05(t,lH), 3.8(s, 3H), 0.9(s, 3H).
  • Example 13 The product of Example 13 was used as starting material for Example 3.
  • the isolated product showed distinct peaks at: NMR(CDCl 3 ) ⁇ 7.4-7.0(m, 1H) , 6.7-6.5(m, 2H), 4.0(t, 1H), 0.9(t, 3H).
  • Example 1 phenoxyacetic acid was replaced by DL-2-phenoxypropionic acid.
  • the purified product showed distinct peaks at: NMR(CDCl 3 ) ⁇ 7.3-6.65 (m, 8H) , 4.45(m, 1H), 3.8(S, 3H) , 0.9(t, 3H) .
  • Example 15 The product of Example 15 was used as starting material for Example 2. The isolated product showed characteristic peaks at: NMR(CDCl 3 ) ⁇ 7.3-6.65(m, 8H) , 4.45(m, 1H), 0.9 (t, 3H). EXAMPLE 17
  • Example 1 phenoxyacetic acid was replaced by 3,3,3-lriphenylpropionic acid.
  • the purified product showed characteristic peaks at : NMR(CDCl 3 ) ⁇ 7.4-6.65(m, 18H), 3.8(s, 3H), 0.9(t, 3H).
  • Example 17 The product of Example 17 was used as starting material in Example 3. After purification the product showed distinct peaks at: NMR(CDCl 3 ) ⁇ 7.4-6.65(m, 18H), 0.9(t, 3H).
  • pehnoxyacetic acid can be replaced by triphenylacetic acid.
  • Example 19 The product of Example 19 can be used as the starting material for Example 3.
  • Example 2 phenoxyacetic acid can be replaced by ⁇ -methoxyphenlyacetic acid.
  • Example 21 The product of Example 21 can be used as the starting material for Example 2.
  • Example 1 phenoxyactic acid can be replaced by 1-indancarboxylic acid.
  • Example 23 The product of Example 23 can be used as the starting material for Example 3.
  • Example 1 phenoxyacetic acid can be replaced by 1,2,3,4-tetrahydro-2-naphthoic acid.
  • EXAMPLE 26
  • Example 25 The product of Example 25 can be used as the starting material for Example 3.
  • phenoxyacetic acid can be replaced by 3,5-dimethylphenoxyacetic acid.
  • Example 27 The product of Example 27 can be used as the starting material for Example 3.
  • the bovine caudate nuclei assay was employed. Bovine brains were obtained fresh from a local slaughterhouse. The caudate nuclei were dissected out and homogenized in Buffer A (50 mM Tris; 1 mM Na 2 -EDTA; 5 mM KCl; 1 mM MgCl 2 ; 2 mM CaCl 2 ; pH 7.4) using a Brinkman Polytron. The homogenate was centrifuged at 40,000 ⁇ g for 20 minutes and washed once. The pellett was resuspended in Buffer A, incubated at 37°C for 15 minutes, then centrifuged. The pellet was washed once more, resuspended to a protein concentration of 5-10 mg/ml in Buffer A and frozen at -70°C until used.
  • Buffer A 50 mM Tris; 1 mM Na 2 -EDTA; 5 mM KCl; 1 mM MgCl 2 ; 2 mM Ca
  • the rat cerebral cortex assay was employed. Male Sprague Dawley rats were killed by decapitation and the brains removed. The cerebral cortices were homogenized in 50 mM Tris; 2mM MgCl 2 (pH 7.4), and centrifuged at 40,000 ⁇ g for 10 minutes. The pellet was washed once, resuspended in Tris/MgCl 2 and incubated with 8 units/ml adenosine deaminase at 37 °C for 30 minutes. The homogenate was centrifuged, washed once, resuspended to a protein concentration of 5-10 mg/ml and frozen at -70°C until use.
  • radioligands were used as radioligands for each of the receptors tested: [ 3 H]-Spiperone 21-24 Ci/mmol for D 2 receptors, [ 3 H]-SCH23390 75-85 Ci/mmol for D 1 receptors, and [ 3 H]-Para aminoclonidine 48-52 Ci/mmol for ⁇ 2 -adrenergic receptors.
  • the radioligands were incubated with various concentrations of competing drug and the appropriate membrane source for periods of ' time as follows: 75 minutes at room temperature for D 2 receptors, 15 minutes at 37°C for D 1 receptors, or 30 minutes at room temperature for ⁇ 2 receptors.
  • D 2 1 ⁇ M butaclamol
  • D 1 1 ⁇ M SCH23390
  • ⁇ 2 1 ⁇ M yohimbine
  • the D 2 assays contained 30 nM Kotaserin in order to block the binding of 3 H-spiperone to 5HT 2 receptors.
  • the assays were terminated by filtration using a 24-port Brandell cell harvester over filters that had been previously soaked in 0.1% polyethyleneimine, and the filters were washed three times by filtration of cold buffer.

Abstract

Optically active or racemic compounds are provided having formula (I). Wherein the radicals R1, R2, R3, R4, R6, X and N are defined in the specification. These compounds are optically active or racemic mixtures capable of binding selectively one or more dopamine D2 receptors, for instance in humans. They are useful in treatment of disorders of the central nervous, cardiovascular, and endocrine systems such as elevated intraocular pressure, schizophrenia and parkinsonism, and for inducing anorexia and weight loss in humans and other mammals.

Description

SUBSTITUTED 2-AMINOTETRALINS
Background of the Invention
Field of the Invention
The invention relates generally to substituted 2-aminotetralins and to processes for preparing such compounds. More particularly, the invention relates to compounds for therapeutic use, in particular in treating disorders of the central nervous, cardiovascular and endocrine systems. The compounds of this invention are also useful for alleviating glaucoma, parkinsonism, and schizophrenia, and for inducing anorexia and weight loss in mammals.
Background of the Prior Art
It is known that various hydroxylated 2-aminotetralins of the general formula
Figure imgf000003_0001
where R1 and R2 are saturated alkyl groups and n is 1 or 2 , are dopamine receptor agonists (McDermed et al., J. Med. Chem. 18 , 362 (1975); Feenstra et al., Arch. Pharmacol. 313, 213 (1980). Many structure-activity relationship studies have been conducted to find compounds with high dopamine-receptor stimulating activity. A survey is contained in Katerinopoulos, H. E., et al., "Structure-Activity Relationships for Dopamine Analogues," Drugs of the Future. Vol. 12, No. 3, 1987, 223-253. Based upon the high activity of apomorphine, many derivatives and simplified structural analogues have been tested and found to have dopaminergic activity. For instance, some of the bicyclic analogues of dopamine, 2-amino-5,6- and 2-amino-6,7-dihydroxytetralin, and their N-alkylated derivatives were tested and showed activity.
In addition, studies have shown that the 5-hydroxy derivatives of 2-aminotetralins possess high potency almost equivalent to that of the 5,6 catechols, with the additional advantage of increased stability, selectivity and duration of biochemical action. These studies have also shown that in bicyclic compounds the size of the- two nitrogen substituents controls activity. For instance, the N-butyl and N,N-dibutyl derivatives of 2-amino-5,6-dihydroxytetralin, dopamine and norapomorphine have little or no dopaminergic activity, while analogues having at least one N-ethyl or N-n-propyl group possess high activity.
Further studies have shown that the D2 receptor potency of dopamine agonists is at a maximum when one of the two N-substituents fits into a receptor niche which, because of size constraints maximally accommodates an n-propyl group Conversely, activity drops off when the propyl group is replaced by the smaller groups ethyl or methyl. When the compound contains no N-substituent at least as small as n-propyl, activity is small or non-existent.
However, the structural requirements for the second N-substituent in such compounds have not been established-Consequently, the search continues for new and better N-substituents to enhance both dopamine receptor binding and activity, especially as shown by in vivo studies designed to test the dopaminergic activity of compounds, such as contralateral turning studies in 6-OH-DA-lesioned rats. See Seiler, Max P., et al., "Structure-Activity Relationships of Dopaminergic 5-Hydroxy-2-aminotetralin Derivatives with Functionalized N-Alkyl Substituents." J. Med. Chem. 1986, 29, 912-917.
The receptor site into which this second N-substituent is thought to interact appears to accommodate a wide variety of large, bulky groups having different functionalities without loss of activity. See McDermed, J. D., et al., J. Med. Chem. 1975, 18, 362; Cannon, J. G., et al., J. Med. Chem. 1977, 20, 1111; and Wikstroem, H., et al., J. Med. Chem. 1982, 25, 925. However, the dopaminergic activity and potency conferred upon the compound by the choice of the second N-substituent is at present, unpredictable so that the search continues for new and better dopamine receptor agonists, especially for compounds showing a high degree of selectivity and specificity as either D1 or D2 receptor agonists. Summary of the Invention
There has now been discovered certain novel compounds having dopaminergic activity and having the structural formula
Figure imgf000006_0001
where R2, R3 and R4 are each selected from the group consisting of H and OA with the provision that at least one of R2, R3 and R4 is H, that R2 and R4 are not both OA; A is H or is selected from the group consisting of hydrocarbyl radicals, for example lower alkyl radicals optionally substituted with aromatic residues (i.e. methyl, ethyl, propyl, benzyl, etc.), as well as and
Figure imgf000006_0002
Figure imgf000006_0003
R5 is selected from the group consisting of alkyl and aromatic residues having between 1 and 12, preferably between 1 and 6, carbon atoms, for example alkyl, optionally subεtitued with aromatic residues, and aromatic residues optionally substituted with alkyl radicals; n is an integer between 1 and 4; R6 is an alkyl chain comprising between 1 and 4 carbon atoms, X is selected from the group consisting of -CH2-, oxygen, sulfur, and nitrogen, with the provision that when X is not -CH2-, R1 is selected from the group consisting of
Figure imgf000007_0001
wherein Z is oxygen, nitrogen or sulfur, wherein Y is selected from the group consisting of hydroxy, nitro, cyano, azido, amino, acylamino, carbpxyamido, trifluoromethyl, sulfate, sulfonamido, halogen, hydrocarbyl, and hetero atom-substituted hydrocarbyl radicals, wherein said heteroatoms are selected from the group consisting of halogen, nitrogen, oxygen, sulfur and phosphorus and said hydrocarbyl radicals comprise from 1 to 12 carbon atoms, and a is an integer of from zero to 3; and with the further provision that when X is -CH2-, R1 is either or
Figure imgf000007_0004
Figure imgf000007_0003
wherein R8 is hydrogen, aryl, or R 6; and further wherein R9 is aryl, R6' -OH, -NH2, -OR6, or -N(R6)2; or R1 is
Figure imgf000007_0005
Figure imgf000007_0002
wherein B is oxygen, sulfur or two hydrogen atoms, and pharmaceutically acceptable salts thereof.
Preferably, R2 is OA and A is H.
It is essential that the compounds in the present invention be an optically active compound or racemic mixture thereof having substantial affinity and selectivity for binding to dopamine D2 receptors, e.g., in a human. In particular, it is found that 2-(N-n-propyl,N-2-[phenyloxy]ethylamino)-5-hydroxytetralin is especially preferred for its high affinity and selectivity for binding to dopamine D2 receptors.
Detailed Description of the Invention The compounds used in the present invention are selected from the group of steroisomers or mixtures thereof of compounds having dopaminergic activity represented by the formula:
Figure imgf000008_0001
where R2, R3 and R4 are each selected from the group consisting of H and OA with the provision that at least one of R2 R3 and R4 is H, that R2 and R4 are not both OA; A is H or is selected from the group consisting of hydrocarbyl radicals, for example lower alkyl radicals, optionally substituted with aromatic residues (i.e. methyl, ethyl, propyl, benzyl, etc.),
Figure imgf000009_0002
R 5 is selected from the group consisting of alkyl and a tic residues having between 1 and 12, preferably between 1 and 6, carbon atoms, for example alkyl residues optionally substituted with aromatic residues and aromatic residues optionally substituted with alkyl radicals; n is an integer between 1 or 4; R6 is an alkyl chain comprising between 1 and 4 carbon atoms; X is selected from the group consisting of -CH2-, oxygen, sulfur, and nitrogen, with the provision that when X is not -CH2-, R is selected from the group consisting of
Figure imgf000009_0001
wherein Z is oxygen, nitrogen or sulfur, wherein Y is selected from the group consisting of hydroxy, nitro, cyano, azido, amino, acylamino, carboxyamido, trifluoromethyl, sulfate, sulfonamido, halogen, hydrocarbyl and hetero atom-substituted hydrocarbyl radicals, wherein said heteroatoms are selected from the group consisting of halogen, nitrogen, oxygen, sulfur and phosphorus and said hydrocarbyl radicals comprise from 1 to 12, preferably 1 to 6, carbon atoms, and a is an integer of from zero to 3, for instance zero to 2; and with the further provision that when X is -CH2-, R1 is either
Figure imgf000010_0002
wherein R8 is hydrogen, aryl, or R6;; and further wherein R9 is aryl, R6, -OH, -NH2, -OR6, or -N(R6)2;
Figure imgf000010_0003
or R1 is
Figure imgf000010_0001
wherein B is oxygen, sulfur or two hydrogen atoms, and pharmaceutically acceptable salts thereof.
Preferably, R2 is OA and A is H.
A is preferably H or is selected from the group consisting of phenyl and alkyl radicals having from 1 to 12 carbon atoms, and more preferably R5 is an alkyl or aryl radical that would serve to extend the activity of the compound in the body, for example phenyl, methyl, t-butyl, o-methylphenyl, o-, m- or p-methoxyphenyl, p-isopropylphenyl or nonyl.
The more preferred groups represented by R are thienyl, phenyl, hydroxyphenyl, furanyl and naphthalenyl, e.g., 2-thienyl, 3-thienyl, 3 -hydroxyphenyl, 4-hydroxyphenyl, etc.
In the more preferred compounds for use in the present invention n is 2, X is oxygen or -CH2- and R2 is OA; and most preferably A is H and R6 is propyl. It is essential that the compounds herein be an optically active or racemic mixtures capable of binding selectively to one or more dopamine D2 receptors, e.g., in a human. In particular, 2-(N-n-propyl,N-2-[phenyloxy] ethylamino)-5-hydroxytetralin is an especially preferred compound because of its high affinity and selectivity for binding to D2 dopamine receptors. Due to their high affinity for binding to D2 dopamine receptors, it is believed that the compounds herein will be useful in the treatment of disorders of the central nervous, cardiovascular, and endocrine systems. In particular it is believed that the compounds herein are useful in the treatment of such conditions in humans as elevated intraocular pressure, schizophrenia and parkinsonism, and for inducing anorexia and weight loss in humans and other mammals.
Particularly preferred compounds are as follows:
Compounds wherein X is oxygen, nitrogen or sulfur and R1 is selected from the group consisting of radicals represented by the general formula:
Figure imgf000011_0001
wherein specific preferred compounds of this group include:
2-(N-n-propyl-N-2-[2-thienyloxy]ethylamino)-5-hydroxytetralin,
2-(N-n-propyl-N-2-[3-thienyloxy]ethylamino)-5-hydroxtetralin,
2-(N-n-propyl-N-2-[2-furanyloxy]ethylamino)-5-hydroxytetralin, 2-(N-n-propyl-N-2-[3-furanyloxy]ethylamino)-5-hydroxytetralin,
2-(N-n-propyl-N-2-[2-(4-methyl)thienyloxy]ethylamino-5-hydroxytetralin,
2-(N-n-propyl-N-2-[2-(3,4,5-trimethy1)thienyloxy]ethylamino)-5-hydroxytetralin,
2-(N-n-propyl-N-2-[2-(5-chloro)thienyloxy]ethylamino)-5-hydroxytetralin,
2-(N-n-propyl-N-2-[2-(4-bromo-5-methyl)thienyloxy]ethylamino)-5-hydroxytetralin,
2-(N-n-propyl-N-2-[2-(4-methyl-5-ethyl)thienyloxy]ethylamino)-5-hydroxytetralin,
Compounds wherein X is oxygen, nitrogen or sulfur and wherein R1 is selected from the group of radicals represented by the formulae:
Figure imgf000012_0001
More preferably, in these compounds Y comprises no more than 5 carbon atoms and a is an integer from 0 to 2. Specific preferred compounds of this group include:
2-(N-n-propyl-N-2-[2-naphthalenyloxy]ethylamino)-5-hydroxytetralin,
2-(N-n-propyl-N-2-[4-indolyloxy]ethylamino)-5-hydroxytetralin,
2-(N-n-propyl-N-2-[2-benzothienyloxy]ethylamino)-5-hydroxytetralin, and
2-(N-n-propyl-N-2-[3-benzothienyloxy]ethylamino)-5-hydroxytetralin; Compounds wherein R1 is phenyl and/or substituted phenyl and is selected from the group of radicals represented by the formula:
Figure imgf000013_0001
and wherein X is oxygen, nitrogen or sulfur. Specific preferred compounds of this group include:
2-(N-n-propyl-N-2-[phenyloxy]ethylamino)-5-hydroxytetralin,
2-(N-n-propyl-N-2-[4-hydroxyphenyloxy]ethylamino)-5-hydroxytetralin, and
2-(N-n-propyl-N-2-[3-hydroxyphenyloxy]ethylamino)-5-hydroxytetralin,
2-(N-n-propyl-N-2-[phenyloxy]ethylamino)-5-methoxytetralin
2-(N-n-propyl-N-2-[phenylamino]ethylamino)-5-hydroxytetralin
2-(N-n-propyl-N-2-[4-hydroxyphenylamino]ethylamino)-5-hydroxytetralin
2-(N-n-propyl-N-3-[phenyloxy]propylamino)-5-hydroxytetra1in
2-(N-n-propyl-N-2-[2,6-dimethylphenyloxy]ethylamino)-5-hydroxytetralin
2-(N-n-propyl-N-2-[3,5-dimethylphenyloxy)ethylamino)-5-hydroxytetralin
Compounds wherein X is -CH2- and R1 is selected from the group consisting of radicals represented by the following formulae:
Figure imgf000013_0002
and wherein B is O, S, or H2. Specific preferred compounds in this group include:
3-[2-[propyl(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)amino]ethyl]-1(3H)-isobenzofuranone
3-[2-[propyl(1,2,3,4-tetrahydro-5-hydroxy-2-naphthalenyl)amino]ethyl]-1(3H)-isobenzofuranone
6- [2-(1,3-dihydro-1-isobenzofuranyl)ethyl]propylamino]-5,6,7,8-tetrahydro-1-naphthalenol
2-(N-n-propyl-N-3,3,3-triphenylpropylamino)-5-hydroxytetralin
2-(N-n-propyl-N-2,2,2-triphenylethylamino)-5-hydroxytetralin
2-(N-n-propyl-N-3,3-diphenylpropylamino)-5-hydroxytetralin
2-(N-n-propyl-N-2,2-diphenylethylamino)-5-hydroxytetralin
2-(N-n-propyl-N-2-phenylpropylamino)-5-hydroxytetralin 2-(N-n-propyl-N-2-phenylpropylamino)-5-methoxytetralin 2-(N-n-propyl-N-2-(-2-methoxy)phenethylamino)-5-hydrσxytetralin
2-[N-n-propyl-N-2-(2-phenyloxy)propylamino]-5-hydroxytetralin
The invention is further illustrated by the following examples which are illustrative of various aspects of the invention, and are not intended as limiting the scope of the inventions defined by the appended claims. EXAMPLE 1
Preparation of 2-[N-n-propyl,N-2-(phenyloxy)ethylamino]-5-methoxytetralin.
A mixture of 2- (N-n-propylamino)-5-methoxytetralin (7.0 g, 0.0319 mol; prepared according to J. Chem. Soc., 1965, pp 26-36), phenoxyacetic acid (4.86 g, 0.0319 mol), and borane trimethylamine complex (2.33 g, 0.0319 mol) was refluxed in xylenes overnight. The cooled reaction mixture was extracted with NaHCO3 and the organic layer was dried over MgS04, filtered and concentrated under reduced pressure. The resulting oil was subjected to flash chromatography (silica; 9:1 pet ether/EtOAc) and product was isolated: NMR of the free base (300 MHz, CDCl3): S 7.3-6.6 (m, 8H), 4.0(t, 2H), 3.7(s, 3H), 3.1-2.5 (m, 9H) , 2.1(m, 1H), 1.7-1.4 (m, 3H), 0.9(t, 3H). The free base thus isolated was converted to a hydrochloride salt by the addition of dry ether-HCl.
EXAMPLE 2
Preparation of 2-[N-n-propyl,N-2-(phenyloxy)ethylamino]-5-hydroxytetralin.
A mixture of pyridine hydrochloride and the product of Example 1 was heated in an oil bath at 200°C. When the reaction was complete (TLC), it was cooled, diluted with H2O, made basic with NH4OH and extracted with ether. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure. The residue was subjected to flash chromatography (silico: C.E. pet ether/EtOAc). The product was dissolved in ether and converted to a hydrochloride salt by the addtition of dry ether-HCl. Anal. Calcd. for C21H27NO2.HCl: C, 69.69; H, 7.80; N, 3.87. Found: C, 69.54; H, 7.90; N, 3.87. NMR of the free base (300 MHz, CDCl3) : δ 7.3-6.6(m, 8H), 4.0(t, 2H), 3.1-2.5 (m, 9H), 2.1(m, 1H), 1.7-1.4 (in, 3H) , 0.9(t, 3H).
EXAMPLE 3
The product of Example 2 was also obtained by dissolving the product of Example 1 in dry dichloromethane and adding a solution of boron tribromide in dichloromethane dropwise at room temperture under nitrogen. After completion, the reaction was poured into a beaker containing NH4OH and ice and stirred for 0.5 h. The organic layer was separated, and the product was purified as in Example 2.
EXAMPLE 4
Preparation of 2-[N-n-propyl,N-3-(phenyloxy)propylamino]-5-methoxytetralin.
In Example 1, phenoxyacetic acid can be replaced by 3-phenoxy-propionic acid.
EXAMPLE 5
Preparation of 2-[N-n-propyl,N-3-(phenyloxy)propylamino]-5-hydroxytetralin.
The product of Example 4 can be used as the starting material for Example 2. EXAMPLE 6
Preparation of 2-[N-n-propyl,N-2-(1-naphthalenyloxy) ethylamino]-5-methoxytetralin.
In Example 1, phenoxyacetic acid was replaced by (1-naphthoxy)-acetic acid. The resulting oil was sujbected to flash chromatography (silica; pet ether) and the product was isolated; characteristic peak of NMR (300 MHz, CDCl3); δ 8.3-6.7 (m,10H), 4.2(m, 2H), 3.85(s, 3H), 1.0(t, 3H).
EXAMPLE 7
Preparation of 2-[N-n-propyl,N-3-(1-naphthalenyloxy) propylamino]-5-hydroxytetralin.
The product of Example 6 was used as the starting material in Example 2. The resulting oil was subjected to flash chromatography and the isolated product showed characteristic peaks at : NMR (CDCl3) δ 8.3-6.6 (m, 10H), 4.2(m, 2H), 0.9(t,3H).
EXAMPLE 8
Preparation of 3-[2-[propyl(1,2,3,4-tetrahydro-5-methoxy-2- naphthalenyl)amino]ethyl]-1(3H)-isobenzofuranone.
In Example 1, phenoxyacetic acid was replaced by phthalide-3-acetic acid. The resulting oil was subjected to flash chromatography and the isolated product showed distinct peaks at: NMR (CDCl3) δ 8.0-6.7(m, 7H) , 5.7(m, 1H), 3.8(s, 3H), 0.9 (t, 3H). Anal. Calc. for C24H29NO3 HCl: C, 69.00, N, 7.27, N, 3.37. Found: C, 69. OS; H, 7.23; N, 3.28. EXAMPLE 9
Preparation of 3-[2-[propyl(1,2,3,4-tetrahydro-5-hydroxy-2-naphthalenyl)amino]ethyl]-1(3H)-isobenzofuranone.
The product of Example 8 was used as the starting material for Example 3. The resulting oil after purification showed distinct peaks at: NMR(CDC13) δ 7.9-6.6(m, 7H), 5.7(m, 1H), 0.95(t, 3H). Anal. Calc. for C23H27NO3 . HCl: C, 68.73; H, 7.02; N, 3.48. Found: C, 68.62; H, 7.09; N, 3.35.
EXAMPLE 10
Preparation of 6-[[2-(1,3-dihydro-1-isobenzofuranyl) ethyl]propylamino]-5,6,7,8-tetrahydro-1-naphthalenol.
The reduction of the product of Example 9 will result in the desired product.
EXAMPLE 11
Preparation of 2-[N-n-propyl,N-2,2-diphenylethylamino)-5-methoxytetralin.
In Example 1, phenoxyacetic acid was replaced by diphenylactic acid. The purified product showed characteristic peaks at: NMR(CDCl3) δ 7.8-6.65(m, 13H), 4.1(t, 1H), 3.8(s, 3H), 3.2(d, 2H), 0.7(t, 3H).
EXAMPLE 12
Preparation of 2-[N-n-propyl,N-2,2-diphenylethylamino]-5-hydroxytetralin. The product of Example 11 was used as starting material in Example 3. After purification the product showed distinct peaks at: NMR(CDCl3) δ 7.8-6.65(m, 13H), 4.1(t, 1H), 3.2 (d, 2H), 0.7(t, 3H). Anal. calc. for C27H31NO . HCl: C, 76.84; H, 7.64; N, 3.32. Observed: C, 77.00; H, 7.69; N, 3.21.
EXAMPLE 13
Preparation of 2-[N-n-propyl,N-3,3-diphenylpropylamino]-5-methoxytetralin.
In Example 1, phenoxyacetic acid was replaced by 3,3-diphenylpropionic acid. The purified product showed distinct peaks at: NMR(CDCl3) δ 7.4-7.2 (m, 11H), 6.65(m, 2H), 4.05(t,lH), 3.8(s, 3H), 0.9(s, 3H).
EXAMPLE 14
Preparation of 2-[N-n-propyl,N-3,3-diphenylpropylamino]-5-hydroxytetralin.
The product of Example 13 was used as starting material for Example 3. The isolated product showed distinct peaks at: NMR(CDCl3) δ 7.4-7.0(m, 1H) , 6.7-6.5(m, 2H), 4.0(t, 1H), 0.9(t, 3H).
EXAMPLE 15
Preparation of 2-[N-n-propyl,N-2-(2-phenyloxy)propylamino]-5-methoxytetralin.
In Example 1, phenoxyacetic acid was replaced by DL-2-phenoxypropionic acid. The purified product showed distinct peaks at: NMR(CDCl3) δ 7.3-6.65 (m, 8H) , 4.45(m, 1H), 3.8(S, 3H) , 0.9(t, 3H) .
EXAMPLE 16
Preparation of 2-[N-n-propyl,N-2-(2-phenyloxy)propylamino]-5-hydroxytetralin.
The product of Example 15 was used as starting material for Example 2. The isolated product showed characteristic peaks at: NMR(CDCl3) δ 7.3-6.65(m, 8H) , 4.45(m, 1H), 0.9 (t, 3H). EXAMPLE 17
Preparation of 2-[N-n-propyl,N-3,3,3-triphenylpropylamino]-5-methoxytetralin.
In Example 1, phenoxyacetic acid was replaced by 3,3,3-lriphenylpropionic acid. The purified product showed characteristic peaks at : NMR(CDCl3) δ 7.4-6.65(m, 18H), 3.8(s, 3H), 0.9(t, 3H). EXAMPLE 18
Preparation of 2-[N-n-propyl,N-3,3,3-triphenylpropylamino]-5-hydroxytetralin.
The product of Example 17 was used as starting material in Example 3. After purification the product showed distinct peaks at: NMR(CDCl3) δ 7.4-6.65(m, 18H), 0.9(t, 3H).
EXAMPLE 19
Preparation of 2-[N-n-propyl,N-2,2,2-triphenylethylamino]-5-methoxytetralin.
In Example 1, pehnoxyacetic acid can be replaced by triphenylacetic acid.
EXAMPLE 20-Preparation of 2-[N-n-propyl,N-2,2,2-triphenylethylamino]5-hydroxytetralin.
The product of Example 19 can be used as the starting material for Example 3.
EXAMPLE 21
Preparation of 2-[N-n-propyl,N-2-[2-methoxy]phenethyl-amino]-5-methoxytetralin.
In Example 1, phenoxyacetic acid can be replaced by α-methoxyphenlyacetic acid. EXAMPLE 22
Preparation of 2-[N-n-propyl,N-2-(2-methoxy)phenethyl-amino]-5-hyroxytetralin.
The product of Example 21 can be used as the starting material for Example 2.
EXAMPLE 23
Preparation of 2-[N-n-propyl,N-(2,3-dihydro-1H-inden-1-yl)methylamino]-5-methoxytetralin.
In Example 1, phenoxyactic acid can be replaced by 1-indancarboxylic acid.
EXAMPLE 24
Preparation of 2-[N-n-propyl,N-(2,3-dihydro-1H-inden-1- yl)methylamino]-5-hydroxytetralin.
The product of Example 23 can be used as the starting material for Example 3.
EXAMPLE 25
Preparation of 2-[N-n-propyl,N-(tetrahydro-2-naphthyl) methylamino]-5-methoxytetralin.
In Example 1, phenoxyacetic acid can be replaced by 1,2,3,4-tetrahydro-2-naphthoic acid. EXAMPLE 26
Preparation of 2-[N-n-propyl,N-(tetrahydro-2-naphthyl) methylamino]-5-hydroxytetralin.
The product of Example 25 can be used as the starting material for Example 3.
EXAMPLE 27
Preparation of 2-[N-n-propyl,N-2-(3,5-dimethylphenyloxy) ethylamino]-5-methoxytetralin.
In Example 1, phenoxyacetic acid can be replaced by 3,5-dimethylphenoxyacetic acid.
EXAMPLE 28
Preparation of 2-[N-n-propyl,N-2-(3,5-dimethylphenyloxy) ethylamino]-5-hydroxytetralin.
The product of Example 27 can be used as the starting material for Example 3.
EXAMPLE 29
To test the selectivity and specificity of the present compounds for binding to dopamine receptors tests were conducted using the following standard procedures.
To test binding to dopamine receptors, the bovine caudate nuclei assay was employed. Bovine brains were obtained fresh from a local slaughterhouse. The caudate nuclei were dissected out and homogenized in Buffer A (50 mM Tris; 1 mM Na2-EDTA; 5 mM KCl; 1 mM MgCl2 ; 2 mM CaCl2; pH 7.4) using a Brinkman Polytron. The homogenate was centrifuged at 40,000 × g for 20 minutes and washed once. The pellett was resuspended in Buffer A, incubated at 37°C for 15 minutes, then centrifuged. The pellet was washed once more, resuspended to a protein concentration of 5-10 mg/ml in Buffer A and frozen at -70°C until used.
To test binding of the compounds to α2-adrenergic receptors, the rat cerebral cortex assay was employed. Male Sprague Dawley rats were killed by decapitation and the brains removed. The cerebral cortices were homogenized in 50 mM Tris; 2mM MgCl2 (pH 7.4), and centrifuged at 40,000 × g for 10 minutes. The pellet was washed once, resuspended in Tris/MgCl2 and incubated with 8 units/ml adenosine deaminase at 37 °C for 30 minutes. The homogenate was centrifuged, washed once, resuspended to a protein concentration of 5-10 mg/ml and frozen at -70°C until use.
The following tritiated drugs were used as radioligands for each of the receptors tested: [3H]-Spiperone 21-24 Ci/mmol for D2 receptors, [3H]-SCH23390 75-85 Ci/mmol for D1 receptors, and [3H]-Para aminoclonidine 48-52 Ci/mmol for α2-adrenergic receptors. The radioligands were incubated with various concentrations of competing drug and the appropriate membrane source for periods of ' time as follows: 75 minutes at room temperature for D2 receptors, 15 minutes at 37°C for D1 receptors, or 30 minutes at room temperature for α2 receptors. Specific binding was defined using 1μM butaclamol (D2), 1 μM SCH23390 (D1), or 1 μM yohimbine (α2). In addition the D2 assays contained 30 nM Kotaserin in order to block the binding of 3H-spiperone to 5HT2 receptors. The assays were terminated by filtration using a 24-port Brandell cell harvester over filters that had been previously soaked in 0.1% polyethyleneimine, and the filters were washed three times by filtration of cold buffer. The filters were then placed in 5 ml scintillation vials to which 4 ml of Beckman Ready-Protein was then added, and each vial was counted for 2 minutes in a Beckman 3801 scintillation counter calibrated for conversion of cpm to dpm. Binding data were analyzed using the Ligand program of Munson and Rodbard (1980). The results are presented as Ki values if the data were best fitted to a one-site model, or as KH and KL values if a two-site model produced the better fit.
Results of the binding tests are summarized in Table 1 below:
Table 1
RECEPTOR AFFINITIES (Ki, nM)
Example D2 (KL) D1(KL) α2
Compound
14 340 1,350 2,600
2 125 12,000 500
12 47 8,964 11,000
9 66 2,130 100
N-0437 110 1,000 190
This table shows high dopamine D2 receptor affinities of compounds chosen from the examples above, with unexpectedly high degrees of selectivity and specificity. The compound N-0437, a potent dopamine D2 a ganist is included as a reference compound for comparative purposes. While particular embodiments of the invention have been described it will be understood of course that the invention is not limited thereto since many obvious modifications can be made and it is intended to include within this invention any such modifications as will fall within the scope of the appended claims.

Claims

We claim:
1. Optically active or racemic compounds having the formula
Figure imgf000027_0001
where R2, R3 and R4 are each selected from the group consisting of H and OA with the provision that at least one of R2, R3 and R4 is H, that R2 and R4 are not both OA; A is
H or is selected from the group consisting of hydrocarbyl radicals said hydrocarbyl radicals being further optionally substituted with radicals selected from the group consisting of aromatic residues and
-
Figure imgf000027_0002
R5 is selected from the group consisting of alkyl and aromatic residues, having between 1 and 12 carbon atoms; n is an integer between 1 and 4; R6 is an alkyl chain comprising between 1 and 4 carbon atoms, X is selected from the group consisting of -CH2-, oxygen, sulfur, and nitrogen, with the provision that when X is not -CH2-, R1 is selected from the group consisting of
Figure imgf000027_0003
wherein Z is oxygen, nitrogen or sulfur, wherein Y is selected from the group consisting of hydroxy, nitro, cyano, azido, amino, acylamino, carboxyamido, trifluoromethyl, sulfate, sulfonamido, halogen, hydrocarbyl and heteroatom-substituted hydrocarbyl radicals, wherein said heteroatoms are selected from the group consisting of halogen, nitrogen, oxygen, sulfur and phosphorus and said hydrocarbyl radicals comprise from 1 to 12 carbon atoms, and a is an integer of from zero to 3; and with the further provision that when X is -CH2-, R1 is selected from a group consisting of -C-Aryl and -C-Z-Aryl wherein R8 is hydrogen,
Figure imgf000028_0003
aryl, or R6; and further wherein R9 is aryl, R6, -OH, NH , or -N(R
Figure imgf000028_0002
6..) 2„; or R1. is
Figure imgf000028_0001
wherein B is oxygen, sulfur or two hydrogen atoms, and a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein A is hydrogen or a hydrocarbyl radical having between 1 and 12 carbon atoms selected from a group consisting of phenyl, alkyl and alkyl substituted with aromatic residues.
3. The compound of claim 2 wherein A is selected from the group consisting of and R5 is
Figure imgf000029_0001
selected from the group of alkyl, alkyl substituted with aryl radicals, and aryl radicals having between 1 and 12 carbon atoms.
4. The compound of claim 1 wherein R5 is selected from the group consisting of phenyl, methyl, t-butyl, o-methylphenyl, o-, m- and p-methoxyphenyl, p-isopropylphenyl, and nonyl.
5. The compound of claim 1 wherein X is selected from the group consisting of nitrogen, oxygen and sulfur, and R2 is OA and A is H.
6. The compound of claim 5 wherein R1 is selected from the group consisting of thienyl, phenyl, hydroxyphenyl, dimethylphenyl , furanyl and napthalenyl .
7. The compound of claim 6 wherein the R1 is selected from the group consisting of 2-thienyl, 3-thienyl, 3-hydroxyphenyl, 2,6-dimethylphenyl, and 4-hydroxyphenyl.
8. The compound of claim 1 where n is 2, X is selected from oxygen or -CH2-, and R2 is OA.
9. The compound of claim 5 wherein Y is selected from the group consisting of hydroxy, nitro, cyano, azido, ammo, acylamino , and cαrboxyamido.
10. The compound of claim 5 wherein Y is selected from the group consisting of trifluoromethyl, sulfate, halogen, hydrocarbyl and heteroatom-substituted hydrocarbyl radicals having between 1 and 12 carbon atoms.
11. The compound of claim 10 wherein the heteroatoms are oxygen, nitrogen or sulfur.
12. The compound of claim 1 wherein R1 is selected from the group consisting of
Figure imgf000030_0001
13. The compound of claim 12 wherein R9 is selected from the group consisting of or -N(R6)2.
Figure imgf000030_0003
14. The compound of claim 12 wherein Rg is selected from the group consisting of aryl, -R6, -NH2, -OH and -OR6.
15. The compound of claim 1 wherein R1 is
Figure imgf000030_0002
and B is selected from the group consisting of oxygen and two hydrogen atoms.
16. The compound of claim 15 wherein B is two hydrogen atoms.
17. The compound of claim 1 wherein R1 is
Figure imgf000031_0001
X is oxygen, and Z is oxygen, nitrogen or sulfur.
18. The compound of claim 1 wherein R1 is selected from the group consising of
Figure imgf000031_0002
wherein X is oxygen, Y comprises 1 to 5 carbon atoms, and a is an integer from 0 to 2.
19. The compound of claim 1 wherein R1 is
Figure imgf000031_0003
X is oxygen and Y is a hydrocarbyl radical comprising 1 to 12 carbon atoms.
20. The compounds of claim 17, 18, or 19 wherein Y comprises no more than 6 carbon atoms, and a is 0 to 2.
21. The compound of claim 19 where Y is methyl and a is
2.
22. The compound of claim 19 wherein a is zero.
23. The compound of claim 20 wherein A is H and R6 is propyl.
24- The compound of claim 1 selected from the group consisting of 2-[N-n-propyl,N-3,3-diphenylpropylamino]-5-hydroxytetralin; 2-[N-n-propyl,N-(2-phenoxy) ethylamino]-5-hydroxytetralin; 2-[N-n-propyl,N-2,2-diphenylethylamino]-5-hydroxytetralin; and 3-[2-[propyl(l,2,3,4-tetrahydro-5-hydroxy-2-naphthalenyl)amino] ethyl]-1(3H)-isobenzofuranone.
25. A method comprising inducing a dopaminergic response in a patient by administering a pharmacologically-effective amount of a compound represented by the formula
Figure imgf000032_0001
where R2, R3 and R4 are each selected from the group consisting of H and OA with the provision that at least one of R2, R3 and R4 is H, that R2 and R4 are not both OA; A is
H or is selected from the group consisting of hydrocarbyl radicals, said radicals being further optionally substituted with radicals selected from the group consisting of aromatic residues and
Figure imgf000032_0002
R5 is selected from the group consisting of alkyl and aromatic residues having between 1 and 12 carbon atoms; n is an integer between 1 and 4; R6 is an alkyl chain comprising between 1 and 4 carbon atoms, X is selected from the group consisting of -CH2-, oxygen, sulfur, and nitrogen, with the provision that when X is not -CH2-, R1 is selected from the group consisting of
Figure imgf000033_0001
Figure imgf000033_0002
wherein Z is oxygen, nitrogen or sulfur, wherein Y is selected from the group consisting of hydroxy, nitro, cyano, azido, amino, acylamino, carboxyamido, trifluoromethyl, sulfate, sulfonamido, halogen, hydrocarbyl and heteroatom-substituted hydrocarbyl radicals, wherein said heteroatoms are selected from the group consisting of halogen, nitrogen, oxygen, sulfur and phosphorus and said hydrocarbyl radicals comprise from 1 to 12 carbon atoms, and a is an integer of from zero to 3; and with the further provision that when X is -CH2-, R1 is selected from a group consisting of
Figure imgf000033_0003
wherein R8 is hydrogen, aryl, or R6; and further wherein R9 is aryl, R6' -OH, -NH2, -OR6, or -N(R6)2; or R1 is
Figure imgf000033_0004
Figure imgf000033_0005
wherein B is oxygen, sulfur or two hydrogen atoms, and a pharmaceutically acceptable salt thereof.
26. The method of claim 23 wherein A is hydrogen, or a hydrocarbyl radical having between 1 and 12 carbon atoms selected from a group consisting of phenyl, alkyl and alkyl substituted with aryl radicals.
27. The method claim 24 wherein A is selected from the group consisting of
Figure imgf000034_0001
and R5 is selected from the group of alkyl and aryl radicals having between 1 and 12 carbon atoms.
28. The method of claim 23 wherein R5 is selected from the group consisting of phenyl, methyl, t-butyl, o-methylphenyl, o-, m- and p-methoxyphenyl, p-isopropylphenyl and nonyl.
29. The method of claim 23 wherein X is selected from the group consisting of oxygen, nitrogen and sulfur, and R2 is OA and A is hydrogen.
30. The method of claim 29 wherein Y is selected from the group consisting of hydroxy, nitro, cyano, azido, amino, acylamino, and carboxyamido.
31. The method of claim 29 wherein Y is selected from the group consisting of trifluoromethyl, sulfate, halogen, and hydrocarbyl and heteroatom-subs tituted hydrocarbyl radicals having between 1 and 12 carbon atoms.
32. The method of claim 31 wherein the heteroatoms are oxygen or sulfur.
33. The method of claim 28 wherein R1 is selected from wherein X is -CH2-.
Figure imgf000035_0001
.
34. The method of claim 33 wnerein R9 is selected from the group consisting of and -N(R6)2.
Figure imgf000035_0002
35. The method of claim 34 wherein R9 is selected from the group consisting of aryl, R6, -NH , -OH, and -OR6.
36. The method of claim 23 wherein R1 is
Figure imgf000035_0003
and X is oxygen, and B is selected from the group consisting of oxygen and two hydrogen atoms.
37. The method of claim 36 wherein B is two hydrogen atoms.
38. The method of claim 36 wherein B is oxygen.
39. The method of claim 23 wherein R1 is
X is oxygen , and Z is oxygen or sulfur .
Figure imgf000035_0004
40. The method of claim 23 wherein R1 is selected from the group consisting of
Figure imgf000036_0001
and X is oxygen, Y comprises 1 to 5 carbon atoms, and a is 0 or .1.
41. The method of claim 23 wherein R1 is
Figure imgf000036_0002
X is oxygen, and Y is a hydrocarbyl radical comprising 1 to 12 carbon atoms.
42. The method of claim 23 wherein R1 is
Y is methyl and a is 2,
Figure imgf000036_0003
43. The method of claim 23 wherein R1 is and a is zero.
Figure imgf000036_0004
44. The method of claim 39, 40 or 41 wherein X is oxygen, Y comprises no more than 5 carbon atoms, and a is 0 to 2.
45. The method of claim 29 wherein R1 is selected from the group consisting of thienyl, phenyl, hydroxyphenyl, furanyl and napthalenyl.
46. The method of claim 45 wherein the napthalenyl is selected from the group consisting of 2-thienyl, 3-thienyl, 3-hydroxyphenyl, and 4-hydroxyphenyl.
47. The method of claim 23 wherein n is 2, X is selected from oxygen or -CH2-, and R2 is OA.
48. The method of claim 47 wherein A is H and R6 is propyl.
49. The method of claim 23 selected from the group consisting of 2-[N-n-propyl,N-3,3-diphenylpropylamino]-5-hydroxytetralin; 2-[N-n-propyl, N-2-(2-phenoxy) ethylamino]-5-hydroxytetralin; 2-[N-n-propyl,N-2,2-diphenylethylamino]-5-hydroxytetralin; and 3-[2 -[propyl (1,2,3,4-tetrahydro-5-hydroxy-2-naphthalenyl) amino]ethyl]-1(3H)-isobenzofuranone.
PCT/US1990/003761 1989-07-05 1990-07-02 Substituted 2-aminotetralins WO1991000727A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37558389A 1989-07-05 1989-07-05
US375,583 1989-07-05

Publications (1)

Publication Number Publication Date
WO1991000727A1 true WO1991000727A1 (en) 1991-01-24

Family

ID=23481446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/003761 WO1991000727A1 (en) 1989-07-05 1990-07-02 Substituted 2-aminotetralins

Country Status (4)

Country Link
EP (1) EP0463119A4 (en)
AU (1) AU6072090A (en)
CA (1) CA2065450A1 (en)
WO (1) WO1991000727A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007885A1 (en) * 1993-09-14 1995-03-23 Zambon Group S.P.A. Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene active on the cardiovascular system
EP0717620A1 (en) * 1993-08-05 1996-06-26 Discovery Therapeutics, Inc. Substituted 2-aminotetralins
WO2001028977A1 (en) * 1999-10-20 2001-04-26 Warner-Lambert Company Method for treating parkinson's disease by administering (-)-5-keto-2-n,n-di-n-propylamino-tetrahydrotetralin
WO2001078713A1 (en) * 2000-04-18 2001-10-25 Axon Biochemicals B.V. Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
US7829587B2 (en) 2008-01-09 2010-11-09 Allergan, Inc. Substituted 2-aminotetralin derivatives as selective alpha 2B agonist

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930022A (en) * 1972-07-03 1975-12-30 Squibb & Sons Inc Certain tetrahydronaphthalenes used in the treatment of cardiac arrhythmia
US4076843A (en) * 1972-07-03 1978-02-28 E. R. Squibb & Sons, Inc. 5,6,7,8-Tetrahydronaphthalene hypotensive agents
US4267373A (en) * 1972-07-03 1981-05-12 E. R. Squibb & Sons, Inc. 5,6,7,8-Tetrahydronaphthalene hypotensive agents
US4314082A (en) * 1978-07-14 1982-02-02 American Hospital Supply Corporation Derivatives of 2-amino-6,7-dihydroxytetrahydro naphthalene (ADTN)
US4410519A (en) * 1979-09-14 1983-10-18 Sandoz Ltd. Tetraline derivatives, their production and pharmaceutical compositions containing them
US4657925A (en) * 1984-08-13 1987-04-14 Nelson Research & Development Co. Method and compositions for reducing the intraocular pressure of mammals
US4743618A (en) * 1983-01-03 1988-05-10 Nelson Research & Development Co. Substituted 2-aminotetralins
US4882352A (en) * 1986-07-28 1989-11-21 Nelson Research & Development Co. Method for treating schizophrenia
US4885308A (en) * 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930022A (en) * 1972-07-03 1975-12-30 Squibb & Sons Inc Certain tetrahydronaphthalenes used in the treatment of cardiac arrhythmia
US4076843A (en) * 1972-07-03 1978-02-28 E. R. Squibb & Sons, Inc. 5,6,7,8-Tetrahydronaphthalene hypotensive agents
US4267373A (en) * 1972-07-03 1981-05-12 E. R. Squibb & Sons, Inc. 5,6,7,8-Tetrahydronaphthalene hypotensive agents
US4314082A (en) * 1978-07-14 1982-02-02 American Hospital Supply Corporation Derivatives of 2-amino-6,7-dihydroxytetrahydro naphthalene (ADTN)
US4410519A (en) * 1979-09-14 1983-10-18 Sandoz Ltd. Tetraline derivatives, their production and pharmaceutical compositions containing them
US4743618A (en) * 1983-01-03 1988-05-10 Nelson Research & Development Co. Substituted 2-aminotetralins
US4657925A (en) * 1984-08-13 1987-04-14 Nelson Research & Development Co. Method and compositions for reducing the intraocular pressure of mammals
US4885308A (en) * 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
US4882352A (en) * 1986-07-28 1989-11-21 Nelson Research & Development Co. Method for treating schizophrenia

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Current Eye Research, Vol. 2, No. 5, issued 1982 December, POTTER et al, "Effects of ergoline derivatives or intraocular pressure and iris function in rabbits and monkeys", see pages 281-288, cited in the application. *
Current Eye Research, Vol. 3, issued 1984, March, POTTER et al, "Alteration in ocular funcitons induced by phenylethylamine analogs of dopamine", see pages 851-859, cited in the application. *
Europe J. Pharmacol, Vol. 105, issued 1984 June, BEAULIEU et al, "N-N-Disubstitued 2-aminotetralins are potent D-2 dopamine Receptor Agonists", see pages 15-21. *
J. Auton. Pharmacol., Vol. 4, issued 1984, BURKE et al, "Effects of Aminotetralins on Intraocular Pressure and Pupillary Function in Rabbitts, see pages 185-192, cited in the application. *
J. Med. Chem, Vol. 29, issued 1986, SEILER et al, "Structure-Activity Relationships of Dopaminergic 5-Hydroxy-2-aminotetralin Derivatives with Functionalized 4-alkyl Substituents, see page 913, specifically. *
J. Med. Chem., Vol. 18, No. 4, issued 1975, McDERMED et al, "Synthesis and Pharmacology of some 2-Aminotetralins Dopamine Receptor Agonists", see pages 362-367. *
J. Med. Chem., Vol. 22, No. 12, issued 1979, HACKSELL et al, "N-Alkylated 2-Aminotetraline Central Dopamine-Receptor Stimulating Activity", see page 1469-1475. *
See also references of EP0463119A4 *
The Lancet, issued 1984 February, MEKKI et al, "Bromocriptine Eyedrops Lower Intravaocular Pressure Without Affecting Prolactin Levels, see page 287-288, cited in the application. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717620A1 (en) * 1993-08-05 1996-06-26 Discovery Therapeutics, Inc. Substituted 2-aminotetralins
EP0717620A4 (en) * 1993-08-05 1997-05-28 Discovery Therapeutics Inc Substituted 2-aminotetralins
WO1995007885A1 (en) * 1993-09-14 1995-03-23 Zambon Group S.P.A. Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene active on the cardiovascular system
US5747513A (en) * 1993-09-14 1998-05-05 Zambon Group, S.P.A. Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene active on the cardiovascular system
WO2001028977A1 (en) * 1999-10-20 2001-04-26 Warner-Lambert Company Method for treating parkinson's disease by administering (-)-5-keto-2-n,n-di-n-propylamino-tetrahydrotetralin
US6683087B2 (en) 2000-04-18 2004-01-27 Axon Biochemicals B.V. Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
WO2001078713A1 (en) * 2000-04-18 2001-10-25 Axon Biochemicals B.V. Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
US6998405B2 (en) 2000-04-18 2006-02-14 H. Lundbeck A/S Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
CN100383126C (en) * 2000-04-18 2008-04-23 H.伦德贝克公司 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
USRE42802E1 (en) 2000-04-18 2011-10-04 H. Lundbeck A/S Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
JP4819280B2 (en) * 2000-04-18 2011-11-24 ハー．ルンドベック アー／エス Phenylethylamine and fused ring variant as catecholamine prodrug and use thereof
USRE43244E1 (en) 2000-04-18 2012-03-13 H. Lundbeck A/S Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
US7829587B2 (en) 2008-01-09 2010-11-09 Allergan, Inc. Substituted 2-aminotetralin derivatives as selective alpha 2B agonist

Also Published As

Publication number Publication date
EP0463119A4 (en) 1992-01-22
CA2065450A1 (en) 1991-01-06
EP0463119A1 (en) 1992-01-02
AU6072090A (en) 1991-02-06

Similar Documents

Publication Publication Date Title
US5118704A (en) Substituted 2-aminotetralins useful as dopaminergics
US4313896A (en) Aryloxyphenylpropylamines
EP0288188B1 (en) 1-phenyl-3-naphthalenyloxy-propanamines
KR101637247B1 (en) Multicyclic compounds and methods of use thereof
DK174599B1 (en) 3-Substituted 3-aroyloxy-propanamines and process for their preparation, pharmaceutical compositions and use of the compounds for the manufacture of drugs
CA2361059A1 (en) Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use
EP1337528B1 (en) Benzothiophene derivative compounds, process of preparation and use thereof
JP2750187B2 (en) Therapeutically effective tetralin derivatives
PL164609B1 (en) Method of obtaining novel derivatives of chromane and thiochromane
CA1335106C (en) Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
CA2296104A1 (en) Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
JP2935137B2 (en) Arylcyclohexylamine-containing neuroprotective drug composition
CZ286038B6 (en) Derivative of 2-aminotetralin being substituted in position 8, process of its preparation, pharmaceutical preparation containing thereof as well as its use
JPH02268151A (en) Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalene and 3-aminochromans
US5274003A (en) Substituted 2-aminotetralins
AU4991999A (en) Methods and compounds for treating depression and other disorders
WO1991000727A1 (en) Substituted 2-aminotetralins
JPH06502635A (en) biologically active amines
CN1181070A (en) Bicyclic isothiourea derivatives useful in therapy
US5358971A (en) Substituted 2-aminotetralins
US5457121A (en) Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5256661A (en) Substituted 2-aminotetralins and pharmaceutical use
EP1028113A1 (en) Fused benzene heterocycle derivatives and utilization thereof
HU187789B (en) Process for preparing 2-amino-1,2,3,4-tetrahydro-naphtalena derivatives
WO1994026703A1 (en) New centrally acting 5-, 6-, 7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins and related structures

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA DK FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990911220

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990911220

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2065450

Country of ref document: CA

WWR Wipo information: refused in national office

Ref document number: 1990911220

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990911220

Country of ref document: EP